BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12396740)

  • 1. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.
    Clement S; Still JG; Kosutic G; McAllister RG
    Diabetes Technol Ther; 2002; 4(4):459-66. PubMed ID: 12396740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.
    Kipnes M; Dandona P; Tripathy D; Still JG; Kosutic G
    Diabetes Care; 2003 Feb; 26(2):421-6. PubMed ID: 12547873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial.
    Clement S; Dandona P; Still JG; Kosutic G
    Metabolism; 2004 Jan; 53(1):54-8. PubMed ID: 14681842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects.
    Wajcberg E; Miyazaki Y; Triplitt C; Cersosimo E; DeFronzo RA
    Diabetes Care; 2004 Dec; 27(12):2868-73. PubMed ID: 15562199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulated first-phase insulin release using Humulin or insulin analog HIM2 is associated with prolonged improvement in postprandial glycemia.
    DiCostanzo CA; Moore MC; Lautz M; Scott M; Farmer B; Everett CA; Still JG; Higgins A; Cherrington AD
    Am J Physiol Endocrinol Metab; 2005 Jul; 289(1):E46-52. PubMed ID: 15713685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.
    Hamann A; Matthaei S; Rosak C; Silvestre L;
    Diabetes Care; 2003 Jun; 26(6):1738-44. PubMed ID: 12766103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.
    Launay B; Zinman B; Tildesley HD; Strack T; Chiasson JL
    Diabetes Care; 1998 Oct; 21(10):1627-31. PubMed ID: 9773721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramadan fasting in diabetes patients on insulin pump therapy augmented by continuous glucose monitoring: an observational real-life study.
    Khalil AB; Beshyah SA; Abu Awad SM; Benbarka MM; Haddad M; Al-Hassan D; Kahwatih M; Nagelkerke N
    Diabetes Technol Ther; 2012 Sep; 14(9):813-8. PubMed ID: 22827507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes.
    Sargin H; Sargin M; Altuntaş Y; Sengül AM; Orbay E; Seber S; Uçak S; Yayla A
    Diabetes Res Clin Pract; 2003 Nov; 62(2):79-86. PubMed ID: 14581144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of oral insulin spray and subcutaneous regular insulin at mealtime in type 1 diabetes.
    Guevara-Aguirre J; Guevara-Aguirre M; Saavedra J; Bernstein G; Rosenbloom AL
    Diabetes Technol Ther; 2007 Aug; 9(4):372-6. PubMed ID: 17705693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
    Gribble FM; Manley SE; Levy JC
    Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications.
    DeWitt DE; Dugdale DC
    JAMA; 2003 May; 289(17):2265-9. PubMed ID: 12734138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes.
    Becker RH; Frick AD; Nosek L; Heinemann L; Rave K
    Diabetes Care; 2007 Oct; 30(10):2506-7. PubMed ID: 17675541
    [No Abstract]   [Full Text] [Related]  

  • 20. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience.
    Clarke WL; Anderson S; Breton M; Patek S; Kashmer L; Kovatchev B
    J Diabetes Sci Technol; 2009 Sep; 3(5):1031-8. PubMed ID: 20144416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.